The EIB-financed project will be organised and implemented at HIPRA facilities in 2021 and 2022.
The European Investment Bank (EIB) is providing a €45 million loan to part-finance HIPRA's investments, working capital requirements and research, development and innovation activities for developing a new COVID-19 vaccine.
HIPRA is a pharmaceutical company focusing on the development, manufacture and sale of vaccines and other immunological solutions for both animals and humans. The COVID-19 pandemic has accelerated the company’s entry into the human health sector thanks to its extensive knowledge and skills in working on the development of a COVID-19 vaccine.
The EIB-financed project will strengthen HIPRA's knowledge and production capacity for coping with current and future pandemics. It will also help to secure a European supply chain for the commercial manufacture of a vaccine based on innovative recombinant protein technology.
By supporting this project, the EIB will help to build scientific knowledge at a European level, while also safeguarding and promoting highly skilled job opportunities. This is the EIB's second loan to HIPRA, after an initial €35 million financing operation signed in two tranches in 2019 and 2021.
EIB Vice-PresidentRicardo Mourinho Félix said: “We are very proud to be working with HIPRA once again, this time for something of such paramount importance as a COVID-19 vaccine. The operation demonstrates the EIB's firm commitment to incentivising innovative skills in health sector companies and to improving people's quality of life.”
HIPRA commented: “The entire HIPRA team is committed to developing the new COVID-19 vaccine. We believe that this project will also help to strengthen a strategic capacity for Europe, enabling it to face new challenges in the future. The EIB is supporting this vision.”
Supporting small and medium-sized enterprises (SMEs) and driving innovation are among the EIB Group’s key priorities in Spain, and the Bank allocated over €4.195 billion and €878 million, respectively, to these goals in 2020.
HIPRA is a pharmaceutical company focused on prevention and diagnosis for animal and human health, with a wide range of highly innovative vaccines and advanced diagnostic services. It is dedicated to offering solutions that improve global health. HIPRA has a strong international presence in more than 39 countries with its own subsidiaries, 11 diagnostic centres and two production plants. Research and development form the core of its knowledge — it allocates 10% of its annual turnover to R&D.
Producing COVID-19 vaccines in Africa came one step closer today after Team Europe formally agreed to support large-scale investment in vaccine production by the Institut Pasteur in Dakar, alongside other support measures. The new manufacturing plant should reduce Africa’s 99% dependence on vaccine imports and strengthen future pandemic resilience on the continent.
The EIB Group today joined a global fundraising effort in the fight against the coronavirus. The European Union-led global Pledging Conference, co-chaired by the President of the European Commission Ursula von der Leyen and other world leaders, aims to raise an initial €7.5 billion to end this pandemic.
The EIB and BioNTech SE (Nasdaq: BNTX, BioNTech) today concluded a EUR 100 million debt financing agreement to support the development of BNT162, the company’s COVID-19 vaccine program. The deal will also allow the company to expand its manufacturing capacity in order to supply the vaccine fast worldwide in response to the pandemic. This will be done at the company’s own risk while the clinical studies are ongoing. BioNTech became the first European company to enter clinical testing, having started a clinical trial in Germany in April and a further clinical trial in the United States at the beginning of May. BioNTech’s development program for BNT162 is one of the broadest development programs globally, with four vaccine candidates being tested in parallel.